FibroBiologics, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-04-30 | -1.35 | -1.33 | +1.85% |
| 2026-02-24 | -2.00 | -0.60 | +70.00% |
| 2025-10-31 | -2.30 | -2.60 | -13.04% |
| 2025-08-14 | -0.12 | — | — |
| 2025-07-31 | -2.40 | -2.40 | — |
| 2025-05-14 | -2.50 | -2.80 | -12.00% |
| 2025-03-31 | -1.40 | -1.80 | -28.57% |
| 2024-11-12 | -1.73 | -0.20 | +88.46% |
| 2024-08-07 | -1.80 | 0.60 | +133.33% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| FBLG | -20.55% | -85.09% | -74.22% | -92.05% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -23.52% | -80.45% | -70.78% | -104.74% |